Evidence map›Paper›PMID 35052483›Full record

ArticleGenes2022

Genome-Wide Analysis in

Mariann M Gabrawy, Nick Khosravian, George S Morcos, Tatiana V Morozova, Meagan Jezek, Jeremy D Walston, Wen Huang, Peter M Abadir, Jeff Leips

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Mariann M GabrawyDepartment of Biological Sciences, University of Maryland, Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA.
Nick KhosravianDepartment of Biological Sciences, University of Maryland, Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA.
George S MorcosDepartment of Biological Sciences, University of Maryland, Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA.
Tatiana V MorozovaProgram in Genetics, Department of Biological Sciences, North Carolina State University, Raleigh, NC 27607, USA.ORCID 0000-0002-8360-8032
Meagan JezekDepartment of Biological Sciences, University of Maryland, Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA.
Jeremy D WalstonBiology of Healthy Aging Program, Division of Geriatric Medicine and Gerontology, School of Medicine, Johns Hopkins University, Baltimore, MD 21224, USA.
Wen HuangDepartment of Animal Science, Michigan State University, East Lansing, MI 48824, USA.
Peter M AbadirBiology of Healthy Aging Program, Division of Geriatric Medicine and Gerontology, School of Medicine, Johns Hopkins University, Baltimore, MD 21224, USA.
Jeff LeipsDepartment of Biological Sciences, University of Maryland, Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA.
University of Maryland, Baltimore County · USJohns Hopkins University · USMichigan State University · USNorth Carolina State University · US

Funding

Technological Assessment and Solutions Core - RC4P30AG021334 · NIA · JOHNS HOPKINS UNIVERSITY · PI Jeremy D Walston · 2003 to 2026
$33.2M
Translational Aging Research Training ProgramT32AG058527 · NIA · JOHNS HOPKINS UNIVERSITY · PI Peter M. Abadir, Esther Seunghee Oh · 2018 to 2026
$4.0M
Age Related Change in Mitochondrial Angiotensin System and Mitochondrial DeclineR01AG046441 · NIA · JOHNS HOPKINS UNIVERSITY · PI ABADIR, PETER M. · 2014 to 2018
$2.3M
Novel Formulation of Topical Losartan for Treatment of Wounds in AgingR21AG043284 · NIA · JOHNS HOPKINS UNIVERSITY · PI ABADIR, PETER M., WALSTON, JEREMY D · 2013 to 2014
$446k
NIA NIH HHS P30 AG021334NIA NIH HHS R01 AG046441NIA NIH HHS R21 AG043284NIA NIH HHS T32 AG058527
6 · The paper itself

Abstract

Despite impressive results in restoring physical performance in rodent models, treatment with renin-angiotensin system (RAS) inhibitors, such as Lisinopril, have highly mixed results in humans, likely, in part, due to genetic variation in human populations. To date, the genetic determinants of responses to drugs, such as RAS inhibitors, remain unknown. Given the complexity of the relationship between physical traits and genetic background, genomic studies which predict genotype- and age-specific responses to drug treatments in humans or vertebrate animals are difficult. Here, using 126 genetically distinct lines of

Indexed as

Genome-Wide Association StudyPhysical Functional PerformanceAge FactorsAngiotensin-Converting Enzyme InhibitorsAnimalsDrosophila melanogasterDrosophila ProteinsFemaleGene Expression Regulation, DevelopmentalLisinoprilMaleMuscle, SkeletalAngiotensin-Converting Enzyme InhibitorsDrosophila ProteinsLisinoprilagingfrailtypersonalized medicine

Identifiers

PMID35052483
PMCPMC8775566
OpenAlexW4206017056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.